Trial record 5 of 771 for:    plaque | "Psoriasis"

A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03167515
Recruitment Status : Completed
First Posted : May 30, 2017
Last Update Posted : April 12, 2018
Information provided by (Responsible Party):
Ferndale Laboratories, Inc.

Brief Summary:
The primary objective of this study is to determine the efficacy and safety of 074-6751 Lotion applied twice daily for four weeks (28 days) in clinical subjects with moderate plaque psoriasis.

Condition or disease Intervention/treatment Phase
Plaque Psoriasis Device: 074-6751 Lotion Not Applicable

Detailed Description:

Skin diseases that cause swelling like psoriasis can be improved by using products applied to cover the skin, keeping the skin moist. Keeping the skin moist will ease the local signs and symptoms, such as skin redness, scaling, and itching in patients with plaque psoriasis. Researchers are testing 074-6751 Lotion in clinical subjects with moderate plaque psoriasis to see if it can act as a protective barrier for the skin so the skin remains moist and heals over time.

074-6751 Lotion is an investigational device. Eligible clinical subjects will be enrolled in the study and apply 074-6751 Lotion twice daily to all psoriasis plaques in the assigned Treatment Area for 28 days. Efficacy will be assessed in the Treatment Area by Investigator's Global Association (IGA) score, clinical signs of psoriasis, pruritus, and percent BSA affected. Safety will be assessed by adverse events (AEs).

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 95 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis
Actual Study Start Date : May 16, 2017
Actual Primary Completion Date : November 28, 2017
Actual Study Completion Date : February 13, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: 074-6751 Lotion Device: 074-6751 Lotion
Apply lotion once in the morning and once in the evening daily at approximately the same time every day with 12 hours between doses. Apply the lotion only to the active psoriatic lesions, as instructed by your study doctor.

Primary Outcome Measures :
  1. Change from Baseline in sum of clinical signs of psoriasis (scaling, erythema, and plaque elevation) scores. [ Time Frame: Day 29 ]
    Scaling, erythema and plaque elevation will each be scored on a 5-point scale where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. These evaluations are an assessment of the overall or "average" degree of each of three key characteristics present within all of the subject's psoriatic lesions in the Treatment Area by the investigator or designee.

Secondary Outcome Measures :
  1. The proportion of subjects with improvement versus Baseline in IGA score. [ Time Frame: Day 29 ]
    The Investigator's Global Assessment (IGA) will be assessed on a 5-point scale where 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.

  2. The proportion of subjects with improvement versus Baseline for each of the clinical signs of psoriasis (scaling, erythema and plaque elevation) [ Time Frame: Day 29 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Subject is a male or non-pregnant female and at least 18 years of age.
  2. Subject has provided written informed consent.
  3. Females must be post-menopausal, surgically sterile, or using an effective method of birth control.
  4. Subject has a clinical diagnosis of stable plaque psoriasis.
  5. Subject is willing and able to apply the test article as directed, comply with study instructions and commit to all follow-up visits for the duration of the study.
  6. Subject, in the investigator's opinion, is in good general health and free of any disease state, skin condition, or physical condition that might impair evaluation of psoriasis, would require use of interfering therapy (e.g., topical, systemic, or surgical).

Exclusion Criteria:

  1. Subject is pregnant, lactating, or is planning to become pregnant during the study.
  2. Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.
  3. Subject has guttate, pustular, erythrodermic, or other non-plaque forms of psoriasis.
  4. Subject has used any of the following topical preparations or procedures in the

    Treatment Area:

    • Emollients/moisturizers within four days prior to Visit I;
    • Topical anti-psoriatic drugs on the body (excluding the scalp) within 14 days of Visit 1; or
    • Phototherapy ( including laser), photo-chemotherapy or other forms of photo based therapy for the treatment of their psoriasis within 30 days of Visit 1.
  5. Subject has used any of the following systemic medications or procedures:

    • Systemic tofacitinib, ampremilast, methotrexate, retinoids, corticosteroids, and cyclosporine or analogous products with in three months of Visit I; or
    • Systemic anti-inflammatory biologic therapy (i.e., FDA-approved or experimental therapy) with in five half-lives of the biologic prior to Visit 1.
  6. Subject is currently using lithium or Plaquenil.
  7. Subject is currently using a beta-blocking medication (e.g., propranolol) or angiotensin converting enzyme (ACE) inhibitor at a dose that has not been stabilized, in the opinion of the investigator.
  8. Subject, in the opinion of the investigator, has had prolonged exposure to natural or artificial sources of ultraviolet (UV) radiation within 30 days prior to Visit 1 or intends to have such exposure during the study that is likely to modify the subject's disease.
  9. Subject is currently enrolled in an investigational drug or device study.
  10. Subject has used an investigational drug or investigational device treatment within 30 days prior to first application of the test article.
  11. Subject has a history of sensitivity to any of the ingredients in the test article.
  12. Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol in the opinion of the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03167515

United States, Florida
Site 03
Tampa, Florida, United States, 33618
United States, Indiana
Site 04
Carmel, Indiana, United States, 46032
Site 05
Plainfield, Indiana, United States, 46168
United States, New Mexico
Site 02
Albuquerque, New Mexico, United States, 87106
United States, North Carolina
Site 01
High Point, North Carolina, United States, 27262
Sponsors and Collaborators
Ferndale Laboratories, Inc.

Responsible Party: Ferndale Laboratories, Inc. Identifier: NCT03167515     History of Changes
Other Study ID Numbers: 074-6751-001
First Posted: May 30, 2017    Key Record Dates
Last Update Posted: April 12, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases